8-K: DaVita Reports Solid Q2 2025 Amidst Cyber Incident

DaVita Inc. announced solid financial and operating results for the second quarter of 2025, despite incurring charges related to a cybersecurity incident and a decline in normalized non-acquired treatment growth.

Summary

• Consolidated revenues for the second quarter of 2025 were $3.380 billion.
• Operating income reached $538 million, with adjusted operating income at $551 million.
• Diluted earnings per share were $2.58, and adjusted diluted earnings per share were $2.95.
• Operating cash flow for the quarter was $324 million, and free cash flow was $157 million.
• The company issued $1.0 billion in 6.75% senior notes due 2033, using a portion of proceeds to repay its revolving line of credit.
• 3.1 million shares of common stock were repurchased at an average price of $144.00 per share, totaling $446 million.
• Total U.S. dialysis treatments for Q2 2025 were 7,186,217, averaging 92,131 treatments per day, a 0.4% per day increase from Q1 2025.
• Normalized non-acquired treatment growth for Q2 2025 compared to Q2 2024 was (0.8)%.
• Revenue per treatment was $404.58, and patient care costs per treatment were $268.36.
• A cybersecurity incident in Q2 2025 resulted in approximately $13.5 million in charges ($1.0 million in patient care costs and $12.5 million in general and administrative expenses) and temporary operational disruption.
• As of June 30, 2025, DaVita provided dialysis services to approximately 283,100 patients across 3,175 outpatient dialysis centers globally.
• Integrated Kidney Care (IKC) had approximately 64,400 patients in risk-based arrangements, representing about $5.3 billion in annualized medical spend.

Sentiment

Score: 5

Explanation: The quarter showed strong sequential improvements in key financial metrics like revenue, operating income, and EPS, and positive free cash flow. However, year-over-year comparisons for net income, EPS, and cash flow were negative, and normalized treatment growth declined. The cybersecurity incident also introduced unexpected costs and operational disruption, leading to a neutral-to-slightly negative overall sentiment.

Positives

• Consolidated revenues increased to $3.380 billion in Q2 2025 from $3.224 billion in Q1 2025.
• Operating income improved to $538 million in Q2 2025 from $439 million in Q1 2025.
• Adjusted operating income increased to $551 million in Q2 2025 from $439 million in Q1 2025.
• Diluted earnings per share increased to $2.58 in Q2 2025 from $2.00 in Q1 2025.
• Adjusted diluted earnings per share increased to $2.95 in Q2 2025 from $2.00 in Q1 2025.
• Operating cash flow significantly improved to $324 million in Q2 2025 from $180 million in Q1 2025.
• Free cash flow turned positive at $157 million in Q2 2025, up from $(45) million in Q1 2025.
• The company repurchased 3.1 million shares for $446 million in Q2 2025, demonstrating capital return to shareholders.
• Revenue per treatment increased to $404.58 in Q2 2025 from $400.14 in Q1 2025, primarily due to normal seasonal improvements.
• Patient care costs per treatment decreased to $268.36 in Q2 2025 from $271.77 in Q1 2025, mainly due to decreased compensation and pharmaceutical costs.
• Integrated Kidney Care patients in risk-based arrangements grew to 64,400, with annualized medical spend increasing to $5.3 billion from $5.2 billion in the prior quarter.

Negatives

• Net income attributable to DaVita Inc. decreased to $199 million in Q2 2025 from $223 million in Q2 2024.
• Diluted earnings per share decreased to $2.58 in Q2 2025 from $2.50 in Q2 2024.
• Operating cash flow for Q2 2025 ($324 million) was significantly lower than Q2 2024 ($799 million).
• Free cash flow for Q2 2025 ($157 million) was significantly lower than Q2 2024 ($654 million).
• Normalized non-acquired treatment growth in Q2 2025 was negative (0.8)% compared to Q2 2024.
• A cybersecurity incident resulted in approximately $13.5 million in charges during Q2 2025, impacting operations temporarily.
• General and administrative expenses increased by $29 million quarter-over-quarter, primarily due to cybersecurity incident costs and increased compensation expenses.

Risks

• External conditions, including general economic, marketplace, and global health conditions, and the impact of global events and political or governmental volatility.
• The impact of the domestic political environment and related developments on the current healthcare marketplace, patients, and business.
• The continuing impact of the COVID-19 pandemic on financial condition and the chronic kidney disease (CKD) population.
• Supply chain challenges and disruptions, including with respect to key services, critical clinical supplies, and equipment from third parties.
• The potential impact of new or potential entrants in the dialysis and pre-dialysis marketplace and innovative technologies, drugs, or other treatments.
• Elevated teammate turnover or labor costs.
• The impact of continued increased competition from dialysis providers and others.
• The concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates.
• A reduction in the number or percentage of patients under commercial plans, including as a result of legislative efforts to restrict or prohibit charitable premium assistance or restrictive plan designs.
• Risks arising from potential changes in or new laws, regulations, or requirements applicable to the company, including the One Big Beautiful Bill Act (OBBBA).
• Ability to successfully implement strategies with respect to Integrated Kidney Care (IKC), Value-Based Care (VBC) initiatives, and home-based dialysis.
• A reduction in government payment rates under the Medicare End Stage Renal Disease program, state Medicaid, or other government-based programs and the impact of the Medicare Advantage (MA) benchmark structure.
• Reliance on significant suppliers, service providers, and other third-party vendors.
• Noncompliance with privacy or security laws or any security breach by the company or a third party, such as the recent cybersecurity incident.
• Legal and compliance risks, including complex and evolving government regulations.
• Ability to attract, retain, and motivate teammates, including key leadership personnel, and manage potential disruptions to business and operations.
• Changes in pharmaceutical practice patterns, reimbursement and payment policies, or pharmaceutical pricing, including with respect to oral phosphate binders.
• Ability to develop and maintain relationships with physicians and hospitals, changing affiliation models for physicians, and the emergence of new models of care.
• Ability to complete and successfully integrate and operate acquisitions, mergers, dispositions, joint ventures, or other strategic transactions.
• Ability to continue to successfully expand operations and services in markets outside the United States, or to businesses or products outside of dialysis services.
• The variability of cash flows, including extended billing or collections cycles due to system defects or the cybersecurity incident.
• The risk of not being able to generate or access sufficient cash in the future to service indebtedness or fund other liquidity needs.
• The effects of natural or other disasters, public health crises, or severe adverse weather events.
• Factors that may impact the ability to repurchase stock under the share repurchase program and the timing of any such repurchases.
• Goals and disclosures related to environmental, social, and governance (ESG) matters, including evolving regulatory requirements.

Future Outlook

For 2025, the company provides guidance for adjusted operating income between $2,010 million and $2,160 million, adjusted diluted net income per share attributable to DaVita Inc. between $10.20 and $11.30, and free cash flow between $1,000 million and $1,250 million. This guidance excludes certain items like cybersecurity costs and foreign currency fluctuations, which may be significant.

Management Comments

• "We're reporting another solid quarter, fueled by our unwavering focus on patient care."
• "We continued to deliver exceptional clinical outcomes for our patients, fostered a positive experience for our caregivers, and delivered on our financial commitments with disciplined execution across our businesses."

Industry Context

The results reflect a mixed environment for healthcare providers. While DaVita demonstrated sequential financial improvements and continued growth in its Integrated Kidney Care segment, aligning with the broader industry shift towards value-based care, the negative normalized non-acquired treatment growth indicates ongoing challenges in patient volume. The cybersecurity incident highlights the increasing operational and financial risks faced by healthcare companies from digital threats.

Stakeholder Impact

• Shareholders: Experienced share repurchases, which can be positive for shareholder value, but faced year-over-year declines in net income and diluted EPS.
• Patients: The company emphasized an unwavering focus on patient care and exceptional clinical outcomes, though a cybersecurity incident caused temporary operational disruption.
• Employees (Caregivers/Teammates): Management stated fostering a positive experience for caregivers, but the forward-looking statements acknowledge risks of elevated teammate turnover or labor costs.
• Creditors: The company issued $1.0 billion in senior notes and repaid its revolving line of credit, indicating active debt management and liquidity planning.

Next Steps

• A conference call to discuss the Q2 2025 results was held on August 5, 2025, at 5:00 p.m. Eastern Time.
• A replay of the conference call will be available on the DaVita Investor Relations website.

Key Dates

Recommendation

While DaVita demonstrated sequential improvements in Q2 2025 and continued its share repurchase program, key year-over-year financial metrics like net income, diluted EPS, and cash flow declined. The negative normalized non-acquired treatment growth and the financial impact of the cybersecurity incident introduce headwinds. The 2025 guidance appears consistent with current trends, but the mixed performance and ongoing operational challenges suggest a 'hold' recommendation for investors awaiting clearer signs of sustained growth and resolution of recent issues.

Keywords

Dialysis, Kidney Care, Healthcare Services, Integrated Kidney Care, Financial Results, SEC Filing, DVA, Patient Care, Corporate Finance, Risk Management